First Patient Dosed in Ph 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
“Relapsed/refractory T-ALL/LBL remains one of the most difficult-to-treat blood cancers, with 40% of adults relapsing after first-line therapy and facing very limited options,” said Jan Davidson-Moncada, MD, PhD, Imviva Biotech Chief Medical Officer. “The successful dosing of our first U.S. patient represents a meaningful milestone in bringing an innovative off-the-shelf CAR-T therapy to this underserved population. We are well-positioned to advance to Phase 2 in the near future and establish CTD402 as a therapeutic option for patients who urgently need better treatments.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.